Home›Azithromycin›Azithromycin + Tacrolimus

Does Azithromycin Interact with Tacrolimus?

CDI records a moderate classification for Azithromycin and Tacrolimus. The stored summary is: Azithromycin may increase tacrolimus blood concentrations, raising the risk of tacrolimus toxicity (nephrotoxicity, neurotoxicity); both drugs can also prolong the QT interval. Monitor tacrolimus levels and renal function when starting or stopping azithromycin. The mechanism involves azithromycin is a weak inhibitor of cyp3a4 and p-glycoprotein, reducing tacrolimus clearance; additive qt-interval prolongation also applies. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is drawn from established clinical references and is provided alongside our FDA-labeling–based data. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Moderate
Tacrolimus Class
Calcineurin Inhibitor Immunosuppressant
Management
Monitor for effects
Data Source
Curated clinical reference

Recorded Mechanism

Azithromycin is a weak inhibitor of CYP3A4 and P-glycoprotein, reducing tacrolimus clearance; additive QT-interval prolongation also applies.

What To Tell Your Doctor or Pharmacist

If you are taking Azithromycin and your doctor is considering prescribing Tacrolimus (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Azithromycin(Zithromax)+💊 Tacrolimus(Astagraf)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
Calcineurin Inhibitor Immunosuppressant
Source
Curated clinical reference

What this means in plain English

Azithromycin may increase tacrolimus blood concentrations, raising the risk of tacrolimus toxicity (nephrotoxicity, neurotoxicity); both drugs can also prolong the QT interval. Monitor tacrolimus levels and renal function when starting or stopping azithromycin.

About Azithromycin and Tacrolimus

Tacrolimus is a Calcineurin Inhibitor Immunosuppressant. You may recognize them by the brand names Zithromax and Astagraf. Both Azithromycin and Tacrolimus carry an FDA boxed warning — the agency's most serious safety designation.

Source and Limitations

This record was curated from clinical references. Its summary is not a verbatim quotation. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: Curated clinical reference

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Azithromycin and Tacrolimus against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations